Waveform-level time-domain simulation comparison study of three shipboard power system architectures

Detailed waveform-level modeling and simulation of three alternative shipboard power system architectures is presented herein. The three system architectures are based on conventional 60Hz medium-voltage ac (MVAC), higherfrequency 240Hz medium-voltage ac (HFAC) and mediumvoltage dc (MVDC) technologies. To support the quantitative assessment and comparison of these three different power system architectures, each technology was modeled using a common representative, notional baseline ship. The baseline ship represents a multi-mission destroyer fitted with an 80MW next generation integrated power system (NGIPS). Modeling of each power system architecture is set forth along with simulation studies for three fault scenarios. Each of the three power system architectures was implemented within the MATLAB/ Simulink environment. Continuity of service was evaluated for each architecture along with a fault scenario using an operability metric. After a brief description of the three power system architectures and the operability metric, quantitative results are presented.Center for Electromechanic

Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)

Background: Thyroid hormone impairment, represented as an alteration in levels of thyroid hormones and a lower fT3/fT4 ratio, has been correlated with a worse prognosis for both cancer and non-cancer patients. The role of baseline thyroid function in patients with metastatic renal cell carcinoma (mRCC) however, has not been studied yet. Materials and Methods: We recorded clinical data, baseline biochemical results, and oncological outcomes from 10 Oncology Units in Italy. We stratified patients into three groups according to the fT3/fT4 ratio value and subsequently analyzed differences in progression-free survival (PFS) and overall survival (OS) in the three groups. We also performed univariate and multivariate analyses to find prognostic factors for PFS and OS. Results: We analyzed 134 patients treated with systemic treatment for mRCC. Median PFS in the low, intermediate, and high fT3/fT4 ratio group were 7.5, 12.1, and 21.7 months respectively (p<0.001); median OS in the three groups were 36.5, 48.6, and 70.5 months respectively (p =0.006). The low fT3/fT4 ratio maintained its prognostic role at the multivariate analysis independently from IMDC and other well-established prognostic factors. The development of iatrogenic hypothyroidism was not associated with a better outcome. Conclusion: We found that baseline thyroid hormone impairment, represented by a low fT3/fT4 ratio, is a strong prognostic factor in patients treated for mRCC in first line setting and is independent of other parameters currently used in clinical practice

Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis.

Background Declines in prostate-specific antigen (PSA) levels at 12wk are used to evaluate treatment response in metastatic castration-resistant prostate cancer (mCRPC). PSA fall by ≥30% at 4wk (PSA4w30) has been reported to be associated with better outcome in a single-centre cohort study.Objective To evaluate clinical relevance of early PSA decline in mCRPC patients treated with next-generation hormonal treatments (NGHTs) such as abiraterone and enzalutamide.Design, setting, and participants This was a retrospective multicentre analysis. Eligible patients received NGHT for mCRPC between 6 January 2006 and 31 December 2017 in 13 cancer centres worldwide, and had PSA levels assessed at baseline and at 4 and/or 12wk after treatment. PSA response was defined as a ≥30% decline (progression as a ≥25% increase) from baseline.Outcome measurements and statistical analysis Association with overall survival (OS) was analysed using landmark multivariable Cox regression adjusting for previous chemotherapy, including cancer centre as a shared frailty term.Results and limitations We identified 1358 mCRPC patients treated with first-line NGHT (1133 had PSA available at 4wk, and 948 at both 4 and 12wk). Overall, 583 (52%) had a PSA4w30; it was associated with longer OS (median: 23; 95% confidence interval [CI]: 21-25) compared with no change (median: 17; 95% CI: 15-18) and progression (median: 13; 95% CI: 10-15). A PSA12w30 was associated with lower mortality (median OS 22 vs 14; hazard ratio=0.57; 95% CI=0.48-0.67; p<0.001). PSA4w30 strongly correlated with PSA12w30 (ρ=0.91; 95% CI=0.90-0.92; p<0.001). In total, 432/494 (87%) with a PSA4w30 achieved a PSA12w30. Overall, 11/152 (7%) patients progressing at 4wk had a PSA12w30 (1% of the overall population).Conclusions PSA changes in the first 4wk of NGHT therapies are strongly associated with clinical outcome from mCRPC and can help guide early treatment switch decisions.Patient summary Prostate-specific antigen changes at 4wk after abiraterone/enzalutamide treatment are important to determine patients' outcome and should be taken into consideration in clinical practice

The U.S. ESRDC advances power system research for shipboard systems

In an effort to advance the research and development capabilities related to shipboard power systems, the U.S. Office of Naval Research created the Electric Ship Research and Development Consortium. This group of seven U.S. universities is working to develop near term and far term research solutions for ship power systems on the all-electric ship. This paper provides an overview of the ESRDC, its successes, resources, and activities related to education and research efforts.Center for Electromechanic

Reference design of 100 MW-h lithium/iron sulfide battery system for utility load leveling

The first year in a two-year cooperative effort between Argonne National Laboratory and Rockwell International to develop a conceptual design of a lithium alloy/iron sulfide battery for utility load leveling is presented. A conceptual design was developed for a 100 MW-h battery system based upon a parallel-series arrangement of 2.5 kW-h capacity cells. The sales price of such a battery system was estimated to be very high, $80.25/kW-h, exclusive of the cost of the individual cells, the dc-to-ac converters, site preparation, or land acquisition costs. Consequently, the second year&#x27;s efforts were directed towards developing modified designs with significantly lower potential costs

Argonne National Laboratory Reports

This report covers the first year in a two-year cooperative effort between Argonne National Laboratory and Rockwell International to develop a conceptual design of a lithium alloy/iron sulfide battery for utility load leveling. A conceptual design was developed for a 100 MW-h battery system based upon a parallel-series arrangement of 2.5 kW-h capacity cells. The sales price of such a battery system was estimated to be very high, $80.25/kW-h, exclusive of the cost of the individual cells, the dc-to-ac converters, site preparation, or land acquisition costs. Consequently, the second year's efforts were directed towards developing modified designs with significantly lower potential costs